Rallis India Limited , a Tata Enterprise, has announced the opening of a special window for re-lodgement of transfer requests of physical shares through newspaper advertisements published on March 25, 2026. The pharmaceutical company has established this facility following SEBI guidelines to assist shareholders with previously rejected or unprocessed share transfer requests.

Special Window for Physical Share Transfer

In accordance with SEBI Circular No. HO/MIRSD/MIRSD_RTAMB/P/CIR/2020/166 dated September 07, 2020, the company has opened a special window until February 5, 2026 to facilitate re-lodgement of transfer of physical shares. This window specifically addresses shares that were lodged prior to April 1, 2019 for transfer and were subsequently rejected, returned, or not attended to due to deficiency in documents, process, or formalities.

Transfer Process and Requirements

The shares that are re-lodged for transfer shall be issued only in demat mode and shall be under lock-in for a period of one year from the date of registration of transfer. Eligible shareholders are requested to submit the necessary original transfer documents along with corrected or missing details and other requisite documents to the company's Registrar and Transfer Agent.

Exclusions and Limitations

Cases involving disputes between transferor and transferee shall not be considered in this special window and may be settled by transferor and transferee through Court/NCLT process. Additionally, shares which have been transferred to Investor Education and Protection Fund shall not be considered under this window for processing.

Regulatory Compliance and Publication

The announcement was made pursuant to Regulation 30 read with Schedule III Part A Para A of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The newspaper advertisement was published in multiple newspapers on March 25, 2026, including Business Standard (English), The Free Press Journal (English), and Navshakti (Marathi).

The communication was signed by Sariga P Gokul, Company Secretary & Compliance Officer, ensuring proper authorization and regulatory compliance. The information is also available on the company's website for shareholder reference.

Solara Active Pharma Sciences Limited has received a significant income tax demand notice of ₹161.92 crores for assessment year 2019-20, the company disclosed in a regulatory filing. The notice was issued by the Deputy Commissioner of Income Tax, Central Circle-3, Thane, following an assessment order passed under Section 143(3) read with Section 147 of the Income Tax Act, 1961.

Tax Demand Details

The substantial tax demand stems from the disallowance of certain expenses claimed by the company in its income tax return for assessment year 2019-20. The company received the communication on March 17, 2026, and made the regulatory disclosure on March 18, 2026.

Company's Response and Action Plan

Solara Active Pharma Sciences has expressed confidence in its position, stating that it believes it has merits in the case and does not expect any material impact on the company financially or otherwise. The pharmaceutical company is preparing to file an appeal against the assessment order before the concerned appellate authority within the prescribed timelines.

Regulatory Compliance Framework

The disclosure was made pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The company provided comprehensive details as required under the regulations, following the SEBI Master circular dated January 30, 2026.

The company has confirmed that no penalties, restrictions, or sanctions have been imposed pursuant to the communication. The matter is limited to the tax demand arising from the disallowed expenses for assessment year 2019-20. The official communication was signed by Company Secretary Pooja Jaya Kumar and will be available on the company's website at solara.co.in.